title: Evaluation of arbekacin anti-MRSA agents for adult in Japan.
abstract: There are a limited number of reports that compare the clinical efficacy of anti-MRSA agents such as arbekacin (ABK), vancomycin (VCM), teicoplanin (TEIC) and linezolid (LZD). There is a tendency for these four agents to show variation in the inflammatory response parameters, in C-reactive protein (CRP) and in white blood cell count (WBC), depending on the administration period. There was no significant difference among the agents in analysis of variance (ANOVA) in the group of days 1-3 (p = 0.0536) but there was some significant difference in the group of days 4-7, as well as days 8-14 (p < 0.001, p < 0.01) in relative variation rate of CRP. Furthermore, we compared in more detail the groups of LZD, VCM and ABK, with a significant decrease of CRP, each of which showed more decrease in comparison with the group of TEIC in the period days 4-7 (p < 0.01). We took 1-hr serum level after days 3-4, with the ABK treatment as the peak concentration (C(peak)). Having made nonlinear logistic regression analysis of CRP and C(peak)/MIC, we concluded that the decrease rate estimable by early inflammatory effect could be decreased to some 40%, assuming that C(peak)/MIC shows the high value within 4 days after ABK treatment.
authors.affiliation: Department of Pharmacy, Kitasato University East Hospital.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Hamada
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Tamura
authors.forename: Ikumi
authors.initials: I
authors.lastname: Koyama
authors.forename: Megumi
authors.initials: M
authors.lastname: Seki
authors.forename: Kazuo
authors.initials: K
authors.lastname: Yago
authors.forename: Keisuke
authors.initials: K
authors.lastname: Sunakawa
authors.forename: Masakazu
authors.initials: M
authors.lastname: Kuroyama
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002097:C-Reactive Protein / Q000032:analysis; D003982:Dibekacin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D008875:Middle Aged
chemical_list: D000890:Anti-Infective Agents; D003982:Dibekacin; D002097:C-Reactive Protein; C031986:arbekacin